Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tajikistan Health News.
Press releases published on August 6, 2025
Voyager Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 6, 2025
- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase …
Keros Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 6, 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor …
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
GlobeNewswire
·
August 6, 2025
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small …
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GlobeNewswire
·
August 6, 2025
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may …
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand growth ZORYVE foam 0.3% received U.S. Food and Drug Administration …
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
GlobeNewswire
·
August 6, 2025
WARREN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment …
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
GlobeNewswire
·
August 6, 2025
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and …
Polymeric Foams Market to Hit $197.8 Billion by 2030
GlobeNewswire
·
August 6, 2025
Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Polymeric Foams: Global Markets” is expected to reach $197.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5% from 2025 through 2030. The …
JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition
GlobeNewswire
·
August 6, 2025
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company’s proposed acquisition by Edwards Lifesciences. JenaValve respectfully disagrees with the FTC's …
ONWARD Medical gibt Ernennung von Lucas Buchanan als Vorstandsmitglied bekannt
GlobeNewswire
·
August 6, 2025
Buchanan ist ehemaliger CFO und COO von Silk Road Medical, wo er erfolgreich ein Medizintechnikunternehmen in der Wachstumsphase skalierte, das schließlich von Boston Scientific übernommen wurde. Buchanan, früher Risikokapitalgeber bei der Vertical Group, …
ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d’administration
GlobeNewswire
·
August 6, 2025
M. Buchanan est l’ancien directeur financier et directeur des opérations de Silk Road Medical, où il a développé avec succès une entreprise de dispositifs médicaux en phase de croissance, aboutissant à son acquisition par Boston Scientific. Ancien …
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight
GlobeNewswire
·
August 6, 2025
New York, USA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight The demand for renal transplant therapeutics is increasing due to several important factors. Chief …
Global Myeloproliferative Disorder Treatment Market is Expected to Showcase an Incremental Growth at a CAGR of ~5% by 2032 | DelveInsight
GlobeNewswire
·
August 6, 2025
New York, USA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Global Myeloproliferative Disorder Treatment Market is Expected to Showcase an Incremental Growth at a CAGR of ~5% by 2032 | DelveInsight The demand for treatments targeting myeloproliferative disorders is …
Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029
GlobeNewswire
·
August 6, 2025
Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care. From laser-based treatments to minimally invasive procedures, leading companies such …
Immix Biopharma Announces Other Serious Diseases Strategy
GlobeNewswire
·
August 6, 2025
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/ …
NADP Foundation Issues Request for Proposals
GlobeNewswire
·
August 6, 2025
DALLAS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- To solicit projects advancing access to oral health care, the National Association of Dental Plans (NADP) Foundation issued its 2025 request for proposal (RFP) on Aug. 1. The RFP seeks projects that: Demonstrate …